(Q48511683)

English

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. (English)

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

phase III clinical trial

0 references

0 references

0 references

quality of life

1 reference

based on heuristic

inferred from title

author name string

Antonio Macciò

1

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Clelia Madeddu

2

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Giulia Gramignano

3

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Carlo Mulas

4

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Carlo Floris

5

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Eleonora Sanna

6

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Maria Chiara Cau

7

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Filomena Panzone

8

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Giovanni Mantovani

9

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

language of work or name

0 references

publication date

20 December 2011

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Gynecologic Oncology

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

124

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

417-425

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

3

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Symptom clusters and quality of life in survivors of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

A review of issues surrounding quality of life among women with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Managing cancer-related anorexia/cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Cancer anorexia-cachexia syndrome: current issues in research and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Definition and classification of cancer cachexia: an international consensus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Medroxyprogesterone acetate in the management of cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Fatigue in gynaecological cancer patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The role of cytokines in cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Anti-inflammatory therapies in cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Interleukin-6 serum levels in patients with gynecological tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

C-reactive protein is a prognostic parameter in patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Psychosocial factors and interleukin-6 among women with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Pain, depression, and fatigue as a symptom cluster in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Cancer cachexia: medical management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

More is better: a multimodality approach to cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Clinical outcomes and contributors to weight loss in a cancer cachexia clinic

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

Megestrol acetate in cancer anorexia and weight loss

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.435

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2011.12.435

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/22198049

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48511683&oldid=1382547881"